Mineur, L.; Vazquez, L.; Belkacemi, M.; Toullec, C.; Bentaleb, N.; Boustany, R.; Plat, F.
Capecitabine/Mitomycin versus 5-Fluorouracil/Mitomycin in Combination with Simultaneous Integrated Boost Intensity-Modulated Radiation Therapy for Anal Cancer. Curr. Oncol. 2023, 30, 8563-8574.
https://doi.org/10.3390/curroncol30090621
AMA Style
Mineur L, Vazquez L, Belkacemi M, Toullec C, Bentaleb N, Boustany R, Plat F.
Capecitabine/Mitomycin versus 5-Fluorouracil/Mitomycin in Combination with Simultaneous Integrated Boost Intensity-Modulated Radiation Therapy for Anal Cancer. Current Oncology. 2023; 30(9):8563-8574.
https://doi.org/10.3390/curroncol30090621
Chicago/Turabian Style
Mineur, Laurent, Léa Vazquez, Mohamed Belkacemi, Clémence Toullec, Newfel Bentaleb, Rania Boustany, and Frederi Plat.
2023. "Capecitabine/Mitomycin versus 5-Fluorouracil/Mitomycin in Combination with Simultaneous Integrated Boost Intensity-Modulated Radiation Therapy for Anal Cancer" Current Oncology 30, no. 9: 8563-8574.
https://doi.org/10.3390/curroncol30090621
APA Style
Mineur, L., Vazquez, L., Belkacemi, M., Toullec, C., Bentaleb, N., Boustany, R., & Plat, F.
(2023). Capecitabine/Mitomycin versus 5-Fluorouracil/Mitomycin in Combination with Simultaneous Integrated Boost Intensity-Modulated Radiation Therapy for Anal Cancer. Current Oncology, 30(9), 8563-8574.
https://doi.org/10.3390/curroncol30090621